Please assess the completion status of the following clinical trial:

Trial Title: MEtronomic TrEatment Option in Advanced bReast cAncer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed HER2-negative locally advanced or metastatic (stage IV) breast cancer.~* Maximum of one prior line of chemotherapy for advanced or metastatic breast cancer.~* Measurable or non-measurable, but radiologically evaluable (except for skin lesions), disease according to RECIST 1.1 criteria.~* Female aged 18 years or older.~* Life expectancy \> 3 months.~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.~* ER-positive disease by local laboratory, determined on most recent available tissue (latest biopsy of metastatic lesion, otherwise prior biopsy or surgical specimen).~* If previously treated with a taxane in the neoadjuvant or adjuvant setting, the period from end of treatment to disease recurrence must have been \> 12 months (\> 365 days).~* Radiation therapy, if given and regardless of site, must be completed at least 2 weeks prior to randomization.~* Normal hematologic status,~* Absolute neutrophil count ≥1000/mm3 (1.0 × 109/L),~* Platelets ≥ 100 × 109/L,~* Hemoglobin ≥ 9 g/dL (≥ 90 g/L).~* Normal renal function: serum creatinine ≤ 1.5 ULN or calculated creatinine clearance ≥ 50 mL/min according to the Cockcroft-Gault formula.~* Normal liver function:~* Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN). In the case of known Gilbert's syndrome, a higher serum total bilirubin (\< 3 × ULN) is allowed.~* Aspartate transaminase (AST) and Alanine transaminase (ALT) ≤ 3 × ULN; if the patient has liver metastases, ALT and AST must be ≤ 5 × ULN.~* Women of child bearing potential must have documented negative pregnancy test within 2 weeks prior to randomization and agree to acceptable birth control (non-hormonal) during and up to 6 months after trial therapy.~* Written Informed Consent (IC) must be signed and dated by the patient and the Investigator prior to starting screening procedures and randomization.~* The patient has been informed of and agrees to data transfer and handling, in accordance with national data protection guidelines.~Exclusion Criteria:~* More than one prior line of chemotherapy for advanced or metastatic breast cancer~* Previous treatment for advanced or metastatic disease with taxanes, or capecitabine or vinorelbine or oral cyclophosphamide.~* More than 2 lines of previous endocrine therapy for locally advanced or metastatic breast cancer.~* Known active central nervous system metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (patients with history of Central Nervous System (CNS) metastases or spinal cord compression are eligible if they are clinically and radiologically stable for at least 4 weeks before first dose of trial treatment and have not required high-dose steroid treatment in the last 4 weeks).~* Peripheral neuropathy grade 2 or higher (CTCAE version 4.0).~* Significant uncontrolled cardiac disease (i.e. unstable angina, myocardial infarction within prior 6 months), patients classified as having a New York Heart Association (NYHA) class III or IV congestive heart failure.~* Pregnant or lactating.~* Prior history of non-breast malignancy (except for adequately controlled basal cell carcinoma of the skin, carcinoma in situ of the cervix, in situ carcinoma of the bladder).~* Any concurrent condition which in the Investigator's opinion makes it inappropriate for the patient to participate in the trial or which would jeopardize compliance with the protocol.~* Contraindications or known hypersensitivity to the trial medication or excipients.~* The use of any anti-cancer investigational agents within 30 days prior to expected start of trial treatment.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Paclitaxel 90 mg/m2 days 1, 8, 15 q4w. Patients will continue to receive assigned treatment until progression or lack of tolerability.
- Arm B (Type: EXPERIMENTAL): Metronomic VEX:~Cyclophosphamide 50 mg orally once daily continuously, Capecitabine 500 mg, orally 3 times a day (1500 mg/day) continuously, Vinorelbine 40 mg orally days 1, 3, 5 each week continuously. Patients will continue to receive assigned treatment until progression or lack of tolerability.

Based on this trial design, predict the completion outcome and termination type (if applicable).